Imaging of ankylosing spondylitis with PET-CT and MRI

Imaging of ankylosing spondylitis with PET-CT and MRI - PET-CT and MRI of ankylosing spondylitis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON35710

Enrollment

Registered

2007-06-08

Start date

2007-06-01

Completion date

Unknown

Last updated

2024-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ankylosing spondylitis Bechterew disease

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosis of ankylosing spondylitis according to the modified New York criteria 2. Treatment with disease modifying anti-rheumatic drugs (DMARDS), corticosteroids up to 10 mg daily and non-steroidal anti-inflammatory drugs (NSAIDs) is permitted, provided that there is a stable dose for at least 2 weeks.

Exclusion criteria

Exclusion criteria: 1. Treatment with any investigational drug within the previous 3 months. 2. Pregnancy or breast-feeding. 3. Implanted pacemaker 4. Renal failure with creatinine clearance

Design outcomes

Secondary

Measure	Time frame
1. Change of joint uptake of PET tracers after etanercept treatment 2. Signs of inflammation on MRI in spinal and/or SI joints (followed by comparison with PET tracer uptake)	—

Primary

Measure	Time frame
The uptake of the PET tracers F18-FDG and C11-(R)PK11195 (and, if applicable F18-Fluoride) in joints of the spine, SI joints and/or peripheral joints	—

Countries

Netherlands

Outcome results